Viatris unit Mylan, former President Rajiv Malik cleared in US Department of Justice generic drug antitrust probe
Pittsburgh: Viatris Inc. has announced that the Antitrust Division of the U.S. Department of Justice (DOJ) has advised that it no longer considers Mylan, and its former President, Rajiv Malik, a subject of its antitrust investigation in the generic drug industry. The Civil Division of the DOJ has also informed the Company that it does not expect to take any further actions in connection with a civil investigative demand related to the pricing and sales of generic drug products.
"This outcome affirms the Company's longstanding position, which it has consistently maintained and asserted, for many years, that Mylan investigated these allegations thoroughly and found no evidence of wrongdoing on the part of Mylan or its employees.
The Company is pleased to put these DOJ investigations behind it and will continue to move forward to vigorously defend itself against the remaining civil lawsuits pertaining to these matters," The Company informed in a release.
Viatris Inc. is a global healthcare company headquartered in the U.S..The Company has global centers in Pittsburgh, Shanghai and Hyderabad, India.
Read also: Kotak Alt infuses Rs 1445 crore for acquisition of API business of Viatris by Matrix Pharma
